Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based VP’ operating in the Health Diagnostics space. If you think a VP’ is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Stephen Buck
VP & GM, Ro Pharmacy of Ro
Follow Stephen Buck:
About Courage Health, Courage Health, Ro: Ro is a telehealth startup that operates digital health clinics for men’s and women’s health, along with smoking cessation.
Meghan Pianta
VP Communications of Ro
Follow Meghan Pianta:
About Ro: Ro is a telehealth startup that operates digital health clinics for men’s and women’s health, along with smoking cessation.
William H. King, IV
Senior Vice President, Strategic Development of Danaher
Mr. King is the Senior Vice President, Strategic Development for Danaher Corporation. Mr. King and his team drive market development, deal sourcing and commercial diligence at Danaher, thus co-owning the M&A process at Danaher with Mr. Daniel Raskas and the Corporate Development team. In addition, he and his team hold responsibility for the strategic planning process, tools and training. Mr. King joined Danaher in 1998 and has held positions as Managing Director of the Special Purpose Systems Motion Control Group, as well as Vice President of Sales and Marketing for the Motion Control Group. Prior to joining Danaher, he held positions of increasing responsibility in live production and logistics for Perdue, Inc. Mr. King has an MBA from Harvard Business School and a BS in Economics from University of Maryland.
Follow William H. King, IV:
About Danaher: Danaher is a global science and technology innovator committed to helping their customers solve complex challenges and improve quality.
Joakim Weidemanis
Group Executive/VP Product Identification Platform of Danaher
Joakim Weidemanis has been Vice President and Group Executive of Danaher Corp. since March 2014. Joakim Weidemanis served as Managing Director of Elster Metering Limited. He served as the Head of Product Inspection at Mettler-Toledo International Inc., since January 2006. From August 2005 to January 2006, he served as Head of Business Development of the Product Inspection Division. He held various management positions at ABB, including from July 2000 to August 2005 when he served as President of the North American water metering systems business and from early 2004 as the Head of the global water metering division that became Elster Water Metering Systems.
Follow Joakim Weidemanis:
About Danaher, Danaher: Danaher is a global science and technology innovator committed to helping their customers solve complex challenges and improve quality.
Christine A. Tsingos
EVP & CFO of Bio-Rad Laboratories
Ms. Christine A. Tsingos is Chief Financial Officer, Executive Vice President of Bio Rad Laboratories Inc. Previously, she was the Chief Operating Officer and Chief Financial Officer at Attest Systems, Inc., a provider of information technology asset discovery and management tools, from August 2002 to November 2002. Prior to that, Ms. Tsingos was a consultant to Attest Systems, Inc. from October 2000 to July 2002. She was the Chief Financial Officer at Tavolo, Inc., an online retailer of gourmet cookware and food, from November 1999 to September 2000, and she was Treasurer, and later Vice President and Treasurer, of Autodesk, Inc., a developer of design software, from May 1990 to November 1999.
Follow Christine A. Tsingos:
About Bio-Rad Laboratories: Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of
Ronald Hutton
Vice President, Treasurer of Bio-Rad Laboratories
Follow Ronald Hutton:
About Bio-Rad Laboratories: Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of
James Stark
Vice President, Corporate Controller of Bio-Rad Laboratories
Follow James Stark:
About Bio-Rad Laboratories: Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of
Mike Crowley
Executive Vice President, Global Commercial Operations of Bio-Rad Laboratories
Follow Mike Crowley:
About Bio-Rad Laboratories: Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of
Timothy Ernst
Executive Vice President, General Counsel & Secretary of Bio-Rad Laboratories
Follow Timothy Ernst:
About Bio-Rad Laboratories: Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of
Junfeng Luo
Co-Founder & Vice President, R&D – NuProbe, China of NuProbe
Junfeng Luo is a Co-Founder and Vice President of R&D at NuProbe, China.
Follow Junfeng Luo:
About NuProbe: An early stage molecular diagnostics company.
Ron Pellegrini
Vice President & Head of Field Service LD/POC of Siemens Healthineers
Ron Pellegrini’s career with Siemens Healthcare spans over 20 years. It began as a licensed Medical Technologist specializing in Chemistry with the U.S. Air Force and at hospitals in Dallas / Fort Worth area. His experience led him to an engineering position with Ciba-Corning Diagnostics. He has held the position of Regional Service Manager and Technical Sales Manager for Chiron & Bayer Healthcare. He held the role of National Technical Sales Director at Siemens and was a Zone Vice President in the Midwest & Western Zones for both the In Vivo and In Vitro businesses prior to taking on his recent role as Vice President, Head of Field Service for LD/POC. Ron was awarded Rookie of the Year, Regional Manager & Director of the year, a three time President’s Club award winner and VP of the Year and a four time APEX winner while in his Service and Technical Sales Leadership positions. He is member of the American Medical Technologists (AMT), a mentor with the American Corporate Partners (ACP) for US Military Members, and is very active as a volunteer within his church community. Ron has been married for the past 29 years with four beautiful children. He enjoys traveling, golf and the watching the Dallas Cowboys. He holds Bachelors degree in Medical Technology from Midwestern State University in Wichita Falls, TX and has a Masters degree in Business.
Follow Ron Pellegrini:
About Siemens Healthineers: Siemens Healthineers is a healthcare technology company that provides diagnostic and therapeutic products and services.
Maynd Jolly
Vice President Strategic Corporate Accounts of Siemens Healthineers
Follow Maynd Jolly:
About Siemens Healthineers: Siemens Healthineers is a healthcare technology company that provides diagnostic and therapeutic products and services.
Sebastian Kronmueller
Vice President, Head of Strategy & Business Development – Laboratory Diagnostics of Siemens Healthineers
Sebastian Kronmueller incubates startup businesses within Healthineers with a focus on novel molecular applications. His current incubation businesses include the Siemens Healthcare Laboratory in Berkeley, California and NEO New Oncology in Cologne, Germany. Previously he led the execution of strategic initiatives as Head of Special Projects for Siemens Healthineers, playing an instrumental role in shaping the strategy of Siemens Healthineers in preparation for the IPO planned in 2018. Before this role he led a project management team for companion diagnostics and software development and was responsible for the carve-out and divestment of the Healthineers Microbiology business. He began his career as strategy consultant with Siemens Management Consulting. Sebastian holds a graduate degree in physics from Ludwig-Maximilians-University in Munich, Germany and a graduate certificate in Management Science and Engineering from Stanford University in Palo Alto, California.
Follow Sebastian Kronmueller:
About Siemens Healthineers: Siemens Healthineers is a healthcare technology company that provides diagnostic and therapeutic products and services.
Howard Dubinett
EVP & COO of Bio-Reference Laboratories
Follow Howard Dubinett:
About Bio-Reference Laboratories: BioReference is the third largest full service clinical diagnostic laboratory in the U.S. providing testing .
Sara Agee Le
VP of Technical Marketing of Oxford Nanopore Technologies
Experienced marketing and communications leader with a proven track record of catapulting life science startup companies. Currently at Oxford Nanopore Technologies disrupting the genomics market with sequencing technology that enables the analysis of anything, by anyone, anywhere — Learn more at www.nanoporetech.com — Previously took @10xGenomics from Chromium #singlecell launch through IPO, launched RNAscope which was acquired by Bio-Techne, secured the acquisition of Bina by Roche, and helped Atomwise pivot from a biopharma services company to an early stage pharmaceutical company disrupting small molecule #drugdiscovery with #AI.
Follow Sara Agee Le:
About Oxford Nanopore Technologies: Oxford Nanopore Technologies develops nanopore-based electronic systems for analyzing single molecules, including DNA, RNA, and proteins.
Richard Compton
Vice President of Commercial Operations of Oxford Nanopore Technologies
Rich joined Oxford Nanopore from Illumina where he played a key role as Vice President and General Manager of the EMEA Region. Metrichor was founded to provide real-time, integrated analysis solutions based on nanopore sensing technology to the Clinical and Applied markets. Prior to Illumina, Rich gained twelve years of experience helping commercial & research customers successfully integrate and deploy enterprise scale software solutions in both research and quality/regulated environments as Vice President & General Manager EMEA of Dassault Systèmes Biovia unit.
Follow Richard Compton:
About Oxford Nanopore Technologies: Oxford Nanopore Technologies develops nanopore-based electronic systems for analyzing single molecules, including DNA, RNA, and proteins.
Allan Ng
VP Marketing of Freenome
Allan Ng is the VP of Marketing at Freenome. In that role, he is responsible for all of the company’s marketing activities. A leader in consumer and technology marketing, Allan brings broad experience marketing leading companies. Previously, he was SVP of Marketing for Livongo, a leading digital health company where he helped scale the company to tens of millions in revenue. While at Google, he led the development of the Google Fiber brand from its infancy, and helped grow Fiber to be a disruptive leader in the telecommunications industry. Prior to Google, Allan was Director of Global Consumer Marketing for Yahoo, where he managed the company’s brand marketing activities. Allan holds a Bachelor of Arts in Economics and Philosophy from Columbia University and an Master of Business Administration from The Haas School of Business at the University of California, Berkeley.
Follow Allan Ng:
About Freenome: Freenome is a biotechnology company with a comprehensive multiomics platform for cancer detection using a routine blood draw.
Michael Wiemer
VP Eng / Co-Founder and CTO of Mojo Vision
Michael Wiemer is the Co-Founder and CTO at Mojo Vision.
Follow Michael Wiemer:
About Mojo Vision: Mojo Vision is developing Mojo Lens, the world’s first AR smart contact lens with a built-in display that delivers Invisible Computing
Eric Johnsen
VP Business Development, Consumer and Enterprise (Fractional) of Mojo Vision
Follow Eric Johnsen:
About Mojo Vision: Mojo Vision is developing Mojo Lens, the world’s first AR smart contact lens with a built-in display that delivers Invisible Computing
Hamid Rategh
Vice President Engineering of Genapsys
Hamid is VP Engineering at GenapSys, joining back in 2012. Hamid has had a successful career developing a wide range of products, from RFICs to adaptive equalizers for optical communication and Mixed-Signal Memory interface products. Prior to joining GenapSys, Hamid was Senior Director of Engineering at Inphi, who acquired his team and product from Scintera Networks. Hamid also cofounded and served as VP of Engineering of Tavanza which was later acquired by Celeritek in 2002 and subsequently by Anadigics in 2003. Hamid holds a PhD in Electrical Engineering from Stanford University, and an MS in Biomedical Engineering from Case Western Reserve University. He earned his BS in Electrical Engineering from Sharif University of Technology.
Follow Hamid Rategh:
About Genapsys: Transform the human condition by building a scalable, affordable genomic sequencing ecosystem that will support research and diagnostics
Kathryn Zavala
Vice President, Business Development & Operations of MedTech Innovator
Follow Kathryn Zavala:
About MedTech Innovator: MedTech Innovator is the largest lifescience accelerator in the world for medical device, digital health, and diagnostic companies
Jeffrey Mathers
Vice President, Commercial Technology, Software Engineering, R&D Platforms, and Architecture of Johnson & Johnson
Follow Jeffrey Mathers:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Vaibhav Narayan
Vice President, Digital Health Innovation of Johnson & Johnson
Follow Vaibhav Narayan:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Ravi Parameswar
Vice President, Head of Global Strategic Insights & Analytics of Johnson & Johnson
Follow Ravi Parameswar:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Nicholas Pachuda
Worldwide Vice President,Orthopedic Innovation,External Innovation & Enabling technologies of Johnson & Johnson
Follow Nicholas Pachuda:
About Johnson & Johnson, Peptilogics: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Amy Foley
Vice President, Product Innovation & Delivery of Johnson & Johnson
As Vice President of Product Innovation & Delivery, Amy Foley leads the Johnson & Johnson portfolio of health and wellness capabilities, including new product and service innovation, creation, implementation, operations, customer service and compliance and quality.
Follow Amy Foley:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Jane Adams
Vice President, Federal Government Affairs of Johnson & Johnson
Follow Jane Adams:
About Johnson & Johnson, Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
David Woods
VP of Product Engineering, Health Technology of Johnson & Johnson
Follow David Woods:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Hartmuth Kolb
Vice President, Neuroscience Biomarkers and Janssen R&D Global Imaging of Johnson & Johnson
Follow Hartmuth Kolb:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Steve Sorensen
Senior VP Technology Services, Supply Chain, Data Integration and Reliability Engineering of Johnson & Johnson
Follow Steve Sorensen:
About Johnson & Johnson, Johnson & Johnson, Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Cat Oyler
Vice President, Global Public Health, Tuberculosis of Johnson & Johnson
Cat Oyler serves as vice-president of global public health (GPH) at Johnson & Johnson (J&J), leading the tuberculosis (TB) focus area strategy team (FAST), and as a member of the GPH executive leadership team. In this role, Cat leads the enterprise TB FAST to deliver on J&J’s aspiration to create a world without tuberculosis through ending mortality from multidrug-resistant tuberculosis. Cat previously served as global head of strategy and operations for J&J Innovation (JJI). She had responsibility for aligning the World Without Disease Accelerator, Lung Cancer Initiative, and JJI organizations to accelerate innovation in order to prevent, intercept and cure disease. Before this, Cat held the role of vice-president of strategy and external innovation for Janssen Research and Development, the global R&D arm of Janssen Pharmaceutical Companies of Johnson & Johnson. Here, she directed the development of the company’s long-term ‘A World Without Disease’ strategy, focusing on transforming human health. Additionally, Cat is an Aspen Institute First Mover Fellow and serves as executive sponsor for the university workstream for Women in Science, Technology, Engineering, Math, Manufacturing, and Design (WiSTEM2D).
Follow Cat Oyler:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Sal Borea
VP of Sales of VoyagerMed
Follow Sal Borea:
About VoyagerMed: A medical tourism marketplace faciliating access to life changing medical innovations from trusted doctors around the world.
Samantha Steinwinder
Vice President of Corporate Marketing of Accolade
Samantha Steinwinder is the Vice President of Corporate Marketing at Accolade, Inc. She oversees Corporate Marketing for the healthcare technology innovator that is reinventing the way individuals and organizations experience healthcare. Ms. Steinwinder is a former Managing Partner at The Concept Agency and Vice President of Weber Shandwick. Samantha received a bachelor of arts in Communication at Menlo College.
Follow Samantha Steinwinder:
About Accolade: Accolade features personalized health and benefits solutions that help to improve experience, outcomes, and healthcare cost for employers.
Tara O’Meara
Vice President, Clinical Development Operations of Bluebird Bio
Tara O’Meara is the Vice President of Clinical Development Operations at bluebird bio. Tara oversees a team responsible for the execution and analysis of bluebird bio’s lentiviral vector based gene therapy development programs. Currently bluebird bio has 4 active programs using ex vivo gene therapy for: cerebral adrenoleukodystrophy, transfusion dependent thalassemia, sickle cell disease and multiple myeloma. bluebird’s objective is to develop and bring to market the most advanced products based on the transformative potential of gene therapy as a one-time treatment option for patients with severe genetic and rare diseases and cancer. Prior to joining bluebird, Tara ran multiple clinical trials in 2 other rare diseases, LAL Deficiency and Pompe disease. Tara served as the clinical project manager for the clinical trials that were used as the basis for the regulatory submissions that led to the approval of Myozyme™ in the United States, Europe, and more than 40 additional countries worldwide. Tara has also been responsible for everything from small Phase II trials to very large, global Phase III trials in multiple therapeutic areas, including rare inherited diseases. Tara holds a BS in biology and a minor in women’s studies from Tufts University.
Follow Tara O’Meara:
About Bluebird Bio: Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
Michael Warmuth
Executive Vice President of Abbott
Michael Warmuth is Executive Vice President, Established Pharmaceuticals, focusing on expanding the global market for Abbott’s portfolio of branded generic pharmaceuticals. He was appointed to his current role in November 2012. Most recently, Mr. Warmuth served as Senior Vice President, Established Pharmaceuticals, which previously operated as part of Abbott’s global pharmaceutical business. Mr. Warmuth joined Abbott in 1986 as part of Abbott’s manufacturing professional development program. He served in a variety of management roles including Senior Vice President, Diagnostics, heading Abbott’s global core laboratory Diagnostics business; Vice President and General Manager, Hematology, in Abbott’s Diagnostics business; Vice President, Global Engineering Services; Divisional Vice President of Pharmaceutical Operations; and Divisional Vice President of Corporate Quality Operations. He earned a bachelor’s degree in business administration from the University of Wisconsin-Whitewater and a master’s degree in business administration from Northwestern University.
Follow Michael Warmuth:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Brian Blaser
EVP, Diagnostics Products of Abbott
Brian Blaser is Executive Vice President, Diagnostics Products, where he leads Abbott’s diagnostics, molecular and point-of-care businesses. He was appointed to his current position in June 2012. Previously, Mr. Blaser served as Senior Vice President, Diagnostics; Vice President, Diagnostics Operations; Divisional Vice President, Global Operations; and Divisional Vice President, Reagent Manufacturing, all in Abbott Diagnostics. Prior to joining Abbott, Mr. Blaser held several positions of increasing responsibility in engineering, finance and operations at Johnson & Johnson, Eastman Kodak and General Motors. He earned a bachelor’s degree in mechanical engineering technology from the University of Dayton and a master’s degree in business administration from Rochester Institute of Technology.
Follow Brian Blaser:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Heather Mason
Executive Vice President, Nutritional Products of Abbott
Heather Mason is Executive Vice President, Nutritional Products. She was appointed to her current role in May 2015. Previously, she served as Executive Vice President, Global Commercial Operations, Abbott Nutrition. Ms. Mason joined Abbott in 1990. She held a number of positions in Abbott’s U.S. pharmaceutical business, including oversight of Abbott’s specialty pharmaceuticals, its diabetes/metabolics and oncology franchises, and managed health care. Ms. Mason also served as Vice President, International Marketing, and Vice President, Latin American Operations, in Abbott’s international pharmaceutical business. Immediately prior to assuming her role in Abbott’s Nutrition business in 2014, Ms. Mason served as Senior Vice President, Abbott Diabetes Care. Prior to joining Abbott, Ms. Mason worked for Quaker Oats and FMC Corporation. She is an advisory board member of the Healthcare Businesswomen’s Association. She earned a bachelor’s degree in engineering from the University of Michigan and a master’s degree in business administration from the University of Chicago.
Follow Heather Mason:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Richard Ashley
EVP, Corporate Development of Abbott
Richard Ashley is Executive Vice President, Corporate Development. His responsibilities include various aspects of corporate strategic planning and business development. Mr. Ashley was appointed to his current position in February 2004. Prior to joining Abbott, he was a senior director at McKinsey and Company, a former managing partner of the firm’s Chicago office, and head of the firm’s Global Leadership and Organization practice. During his 31 years with McKinsey, Mr. Ashley consulted with clients in the healthcare, energy and industrial manufacturing industries across a wide range of business and organizational issues. Mr. Ashley is a member of the executive committee of the board of directors of Junior Achievement of Chicago and a former member of the Civic Committee of the Commercial Club of Chicago. He is a member of The Economic Club of Chicago, the American Bar Association, and the Wisconsin Bar Association. He earned a bachelor’s degree in political science and master’s degree in business administration from Northwestern University. He also holds a juris doctorate from the University of Wisconsin Law School.
Follow Richard Ashley:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Corlis Murray
Senior Vice President, Quality Assurance, Regulatory & Engineering Services of Abbott
Corlis Murray is Senior Vice President, Quality Assurance, Regulatory and Engineering Services. She was appointed to her current position in February 2012. Previously, she served as Vice President, Global Engineering Services. Ms. Murray joined Abbott in 1989. Since then, she has held a number of management positions in quality, operations and engineering in Abbott’s Diagnostics and Nutrition businesses. In Abbott Nutrition, she served as Divisional Vice President, Quality Assurance; Divisional Vice President, Manufacturing; and Divisional Vice President, Operations Services. Prior to joining Abbott, Ms. Murray worked at Recognition Equipment and Xerox Corporation. She is a board member of The Clara Abbott Foundation. She earned a bachelor’s degree in mechanical engineering from Southern University in Baton Rouge, Louisiana.
Follow Corlis Murray:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
John Capek
Executive Vice President of Abbott
John Capek, Ph.D., is Executive Vice President, Ventures. Dr. Capek was appointed to his current position in June 2015. In this role, he leads Abbott’s venture investment organization as well as new ventures, including Abbott Electrophysiology. Previously, he had served as Executive Vice President, Medical Devices, and Senior Vice President, Abbott Vascular, heading up Abbott’s global vascular business. Before joining Abbott, Dr. Capek served in various management roles at Guidant Corporation, including president, Guidant Vascular Intervention and vice president and general manager of Bioabsorbable Vascular Solutions. He also served as vice president and general manager of Guidant Germany and vice president, marketing, Guidant Cardiac Rhythm Management Group. Before joining Guidant, Dr. Capek was manager of New Product Technology at Eli Lilly & Company. He has a bachelor’s degree in biomedical engineering, a master’s degree in biomedical engineering, a master’s degree in electrical engineering, a Ph.D. in biomedical engineering and a master’s degree in business administration from Rensselaer Polytechnic Institute.
Follow John Capek:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Roger Bird
Senior Vice President, U.S. Nutrition of Abbott
Roger Bird is Abbott’s Senior Vice President, U.S. Nutrition. He was appointed to this role in February 2015. Prior to assuming his current position, Roger served as Divisional Vice President, General Manager for our Nutrition business in China and Hong Kong. Roger came to Abbott in 1983 from the Dial Soap Company, where he worked as a sales representative. He joined Abbott as Trade Sales Manager in our Nutrition organization, and has served in this business throughout his Abbott career, contributing to our company’s success in both the U.S. and Asia. While leading Abbott’s nutrition business in China, he oversaw the successful launch of Similac Eleva and Similac Qinti, two infant formula products that significantly strengthened Abbott’s presence in this important market. Throughout his career, Roger has taken real pride in contributing to the Abbott Nutrition mission of providing high-quality products that help improve the lives of people of all ages, all around the world. In addition to his responsibilities with Abbott. Roger serves on the Board of the Grocery Manufacturers Association. Roger earned his bachelor’s degree in Business Management from Weber State University in Ogden, Utah.
Follow Roger Bird:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Steve Fussell
Executive Vice President, Human Resources of Abbott
Steve Fussell is Executive Vice President, Human Resources. He was appointed in February 2013. Mr. Fussell joined Abbott in 1996, as Divisional Vice President, Compensation and Benefits. He was promoted to Vice President, Compensation and Development in 1999, and to Senior Vice President, Human Resources in 2005. Prior to Abbott, he held human resources leadership positions at Nestlé and Shell. Mr. Fussell is Chairman of the Board and President of the Clara Abbott Foundation and a board member of the Abbott Fund. He is an author and speaker on a wide variety of subjects and has served as a guest lecturer at Cornell and other universities. In 2010, he was named to the HR Honor Roll by Human Resources Executive magazine. He earned a bachelor’s degree from Louisiana State University in Baton Rouge.
Follow Steve Fussell:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Jean-Yves Pavée
Senior Vice President of Abbott
Jean-Yves Pavée is Senior Vice President, Developed Markets for Abbott’s Established Products Division. He was appointed to his role in July 2013. Previously, he served as Divisional Vice President, EMEA East, and Division Vice President, Pharmaceuticals, Europe South. Mr. Pavee joined Abbott in 1992, after serving as European Sales Manager, France for Aguettant, S.A. Mister Pavée received his undergraduate degree from the Ecole Supérieure des Sciences Commerciales d’Angers, France; and his MBA from HEC Paris MBA, Jouy-en-Josas, France.
Follow Jean-Yves Pavée:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Jaime Contreras
SVP, Core Laboratory Diagnostics, Commercial Operations of Abbott
Jaime Contreras is Senior Vice President, Core Laboratory Diagnostics, Commercial Operations. He was appointed to his current role in September 2013. Previously, he served as Vice President, Diagnostics, Global Commercial Operations. Mr. Contreras joined Abbott in 1992, and has held various management positions in Abbott’s Diagnostics Division, including Vice President for Europe, Africa and the Middle East; and General Manager of Commercial Operations in Spain, Portugal and Mexico. Prior to joining Abbott, Mr. Contreras was area director for Bayer in Mexico. Mr. Contreras serves on the board of directors of the European Diagnostic Manufacturers Association (EDMA) and on the Board of Directors of the Clara Abbott Foundation. He earned a bachelor’s degree in industrial design from the Universidad Autonoma Metropolitana and a master’s degree in business administration with specialty in Financial Engineering from the Universidad del Valle de Mexico.
Follow Jaime Contreras:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Brian Yoor
Senior Vice President Finance & Chief Financial Officer of Abbott
Brian Yoor is Senior Vice President Finance and Chief Financial Officer. He was appointed to his current position in June 2015. He previously served as Vice President, Investor Relations. Brian joined Abbott in August 1997, and held various financial management positions of increasing responsibility, including Controller positions in the pharmaceutical, nutrition, and diagnostic businesses, before being asked to lead Abbott’s Investor Relations effort in January 2013. Prior to joining Abbott, Brian was a certified public accountant with Arthur Andersen and held financial positions in the consumer industry with the Scotts Company and Newell Rubbermaid. “In Abbott Finance, we are the stewards that enable financial reliability and growth for Abbott, “ Says Brian. “ A strong, growing company is better able to help people around the world live their healthiest lives.” Brian serves on the board of the Clara Abbott Foundation. He is a member of NIRI, the National Investor Relations Institute. He earned his bachelor’s degree in accounting at the University of Toledo in Ohio.
Follow Brian Yoor:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Hubert L. Allen
Executive Vice President, General Counsel & Secretary of Abbott
Hubert L. Allen is Executive Vice President, General Counsel and Secretary. He was appointed to his current role in January 2013. Previously, he served as Divisional Vice President and Associate General Counsel, Established Pharmaceuticals. Mr. Allen joined Abbott in 2006 as Senior Counsel, supporting the Pharmaceutical Products Division. He has held various positions within the legal department, including Divisional Vice President and Associate General Counsel, Pharmaceutical Products Group; Section Head, Nutrition Legal Operations; and Division Counsel, supporting the Pharmaceutical Products Division. Prior to joining Abbott, Mr. Allen was Assistant General Counsel for McKesson Corporation. He graduated with a bachelor’s degree from the College of Social Studies at Wesleyan University in Middletown, Connecticut; a master’s degree in Politics from Princeton University in Princeton, New Jersey, and a juris doctorate from Yale Law School in New Haven, Connecticut.
Follow Hubert L. Allen:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Elaine Leavenworth
SVP, Chief Marketing & External Affairs Officer of Abbott
Elaine Leavenworth is Senior Vice President, Chief Marketing and External Affairs Officer. She was appointed to this role in December 2014. Previously, she had served as Abbott’s Vice President, Government Affairs. Ms. Leavenworth joined Abbott in 1991 and held various management positions of increasing responsibility in Abbott’s Nutrition, International, and Health Systems divisions. She was elected a corporate officer in July of 1999. Prior to joining Abbott, Ms. Leavenworth was a principal with the consulting firm Louden & Company, where her work focused on marketing and strategy assignments for health care providers, suppliers, investors and associations. While at Louden & Company, she published numerous articles and several books, including The Hospital Group Purchasing Outlook, Home Care Joint Venturing, The Older Adult Market and Home Care – HMO/PPO Perspectives. Ms. Leavenworth also held marketing positions at G.D. Searle & Co. and American Hospital Supply Corporation. Ms. Leavenworth serves on the board of trustees of the Goodman Theater, the board of directors of the National Association of Manufacturers, the Board of Advisors of the Duke Global Health Institute, the Board of Governors of the Bryce Harlow Foundation, and the Women’s Advisory Board of the Girl Scout Council of the Nation’s Capital. She is a member of the Economic Club of Chicago, The Chicago Network (where she served previously on the board of directors), and the Women’s Forum of Washington, D.C. She also served on the board of the Clara Abbott Foundation from 2005 to 2014. She earned a bachelor’s degree in health policy from Duke University and a master’s degree in business administration from Northwestern University.
Follow Elaine Leavenworth:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Thomas Frinzi
Senior Vice President of Abbott
Thomas Frinzi is Senior Vice President of Abbott’s vision business, which includes a broad ophthalmology portfolio across the areas of cataracts, refractive surgery (LASIK) and eye health products. He was appointed to his position in January 2016. Prior to joining Abbott, Mr. Frinzi held a number of leadership positions in ophthalmology and medical device companies. Most recently, he served as President and CEO of WaveTec Vision, a developer of surgical systems for eye surgery. He also held senior positions in commercial operations, business development, and sales and marketing at Bausch & Lomb Surgical, Refractec and Johnson & Johnson. In recognition of his leadership, expertise and vision in the field, Mr. Frinzi was awarded the 2015 Ophthalmology Innovation Award by the Ophthalmology Innovation Summit. He earned a bachelor’s degree in political science from the University of Tampa.
Follow Thomas Frinzi:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Keith Patton
VP Software Development of Zerigo Health
Follow Keith Patton:
About Zerigo Health: Clarify Medical is a developer of a handheld medical device used to treat psoriasis, eczema, and vitiligo .
Steve Pham
Vice President of Clinical and Research Affairs of Eko Health
Steve Pham is a practicing emergency medicine physician, the head of medical and research affairs at Eko, and a new father. His passion is translating between digital and clinical insights.
Follow Steve Pham:
About Eko Health: Eko develops AI-powered digital tools to detect and monitor heart and lung disease
Tyler Crouch
Co-Founder, VP of Mobile Engineering & Product Development of Eko Health
Follow Tyler Crouch:
About Eko Health: Eko develops AI-powered digital tools to detect and monitor heart and lung disease
Jeffrey Bornstein
SVP of GE Ventures
Jeffrey S. Bornstein is currently a Senior Vice President and Chief Financial Officer for GE Company.Prior to his current role Bornstein served as Chief Financial Officer of GE Capital and Senior Vice President of GE Company.Bornstein joined GE in 1989 with the GE Power Systems’ Financial Management Program. In 1992, he joined the GE Corporate Audit Staff and then became Executive Audit Manager. In 1996, he was named Chief Financial Officer for GE Aircraft Engine Services and Vice President in 1998. In 1999, he was promoted to Chief Financial Officer of GE Plastics and served as their CFO until 2002.He is on the board of Northeastern University and buildOn. He has also been involved in a number of youth programs. He received his B.S. in Business Administration from Northeastern University.
Follow Jeffrey Bornstein:
About General Electric: GE Ventures combines capital, expertise, infrastructure, and the GE global network to help accelerate the growth of businesses.
James Hinrichs
Executive Vice President and Chief Financial Officer of Alere
James (“Jim”) Hinrichs joined Alere in April 2015 as Executive Vice President and Chief Financial Officer, with global responsibility for Finance, Accounting, Procurement, IT and Shared Services. Prior to his appointment as CFO of Alere, Jim Hinrichs was CFO at CareFusion Corp., a global medical technology corporation, since 2010. He held this position through the completion of Becton Dickinson’s acquisition of CareFusion in March 2015. Prior to this role, Hinrichs served as SVP of Global Customer Support and, before that, Corporate Controller of CareFusion. Previously, he was Executive Vice president and Controller of Cardinal Health, CFO of Cardinal Health’s Clinical and Medical Products segment and CFO of Cardinal Health’s Healthcare Supply Chain Services segment.. He joined Cardinal Health in February 2004, following 12 years of finance and marketing roles at Merck & Co. and two years as the CFO of SangStat Medical Corporation.
Follow James Hinrichs:
About Alere: Alere provides diagnostics and health management solutions for infectious, heart and cancer-related diseases and drug addicts.
John Bridgen
SVP, Business Development of Alere
John Bridgen, Ph.D. has served as Senior Vice President, Business Development since July 2010, after serving as our Vice President, Business Development from June 2006 to July 2010. He served as our Vice President, Strategy from September 2005 to June 2006. Dr. Bridgen joined our Company in September 2002, upon our acquisition of Wampole Laboratories, LLC. Dr. Bridgen served as President of Wampole from August 1984 until September 2005. Prior to joining Wampole, Dr. Bridgen had global sales and marketing responsibility for the hematology and immunology business units of Ortho Diagnostic Systems Inc., a Johnson & Johnson company.
Follow John Bridgen:
About Alere: Alere provides diagnostics and health management solutions for infectious, heart and cancer-related diseases and drug addicts.
Mark Gladwell
Senior Vice President, Global Operations of Alere
Mark Gladwell has served as Senior Vice President, Global Operations since January 2015. From January 2014 through January 2015, he held the role of Vice President, Operations for North America, Europe, Middle East and Africa. From September 2011 through December 2013, Mr. Gladwell served as Vice President of Operations for North America and as President and General Manager of one of Alere’s key manufacturing facilities in North America. From 2007 to 2010 Mr. Gladwell was Vice President, Quality and Technical Service for Alere. From 2005 to 2007, he served as a director covering multiple functions in the start-up of Alere Technology Limited where he focused on the development and manufacture of the Alere home BNP product. Prior to 2005 Mr. Gladwell held a variety of operations, quality and project leadership positions in North America and Europe for Alere, Johnson & Johnson, Agfa Gavert and DuPont. Mr. Gladwell has more than 18 years of experience in manufacturing high-volume, high-technology in-vitro diagnostics and medical devices.
Follow Mark Gladwell:
About Alere: Alere provides diagnostics and health management solutions for infectious, heart and cancer-related diseases and drug addicts.
Robert Hargadon
VP, Global Human Resources of Alere
Robert Hargadon is the Vice President – Global Human Resources Alere Inc. He joined Alere Inc. as Vice President, Global Culture and Performance in October 2010. He has over 30 years of experience in human resources, leadership and organization development. Mr. Hargadon served as Vice President, Human Resources at drugstore.com, an online pharmacy, from November 2006 through October 2010. Prior to that, Mr. Hargadon was General Manager, Corporate Learning and Development at Microsoft from September 2005 to April 2006 . He held various Human Resources leadership positions at Boston Scientific Corporation, a medical device manufacturer, from 1997 to 2005 , Including Vice President of International Human Resources, Vice President, Leadership Development from September 1997 to June 2005 . Mr. Hargadon also served as Vice President, Learning and Development at Fidelity investments from 1993 to 1997. Mr. Hargadon also has 15 years of experience with the consulting firms Novations Group, Inc. and Harbridge House, which was acquired by PricewaterhouseCoopers LLP.
Follow Robert Hargadon:
About Alere: Alere provides diagnostics and health management solutions for infectious, heart and cancer-related diseases and drug addicts.
Saranyan Vigraham
VP of Engineering of Petuum
Follow Saranyan Vigraham:
About Petuum: Petuum, Inc. is building a platform that serves the full spectrum of Artificial Intelligence
Alexander Kayne
EVP, General Counsel & Secretary of Genoa
Alexander (Aly) Kayne joined Genoa in 2015 as Executive Vice President, General Counsel and Secretary. Kayne comes to Genoa having most recently served as General Counsel for Omnicare, where he developed the company’s legal department and played a key role in helping successfully resolve several complex legacy legal matters. Kayne was a Partner with Dewey & LeBoeuf LLP in its New York Litigation Department prior to joining Omnicare. He has represented companies from a variety of industries, including healthcare, banking, insurance, and energy, and his practice focused on complex commercial and securities cases in federal and state courts including cases involving federal and governmental regulatory agencies. In 2014, Kayne was recognized by Corporate Board Member as one of the elite “General Counsel to Watch,” which identifies the brightest and most respected chief legal counsel in the industry.
Follow Alexander Kayne:
About Genoa: Genoa, a QoL Healthcare Company is the pharmacy and telepsychiatry provider serving the behavioral health and addiction treatment.
David Franklin
Vice President, Commercial Operations of Intarcia Therapeutics
Mr. Franklin joined Intarcia in March 2006 as Vice President, Commercial Operations. Prior to joining Intarcia, Mr. Franklin was Senior Vice President, US Business Unit and Acting Senior Vice President, Global Marketing for Idenix Pharmaceuticals. As head of the US Business from March 2005 through March 2006, Mr. Franklin developed and executed plans for the commercialization of telbivudine, an antiviral for the treatment of chronic hepatitis B, and built the US Business Unit, an organization comprising approximately 40 Medical, Marketing and Sales personnel. From June 2003 until March 2005, Mr. Franklin served as Vice President, Commercial Operations, leading the Idenix Global Marketing group, directing brand development for telbivudine and for a phase II hepatitis C drug candidate and leading commercial efforts to form a global co-promotion and licensing alliance with Novartis AG. Prior to these responsibilities, Mr. Franklin held positions of increasing responsibility with Idenix as Executive Director, Marketing and Corporate Communications and Director, Marketing and played key roles in multiple private and public financing transactions and in business development and licensing transactions. Prior to joining Idenix in 1998, Mr. Franklin was Senior Product Manager, HIV Products for Bristol-Myers Squibb Co. with responsibility for Zerit and Videx, two antiviral therapies for the treatment of HIV infection. Prior to joining the HIV Products Division, Mr. Franklin held sales and sales administration positions within the Bristol-Myers Squibb Oncology Division from 1990 to 1995, responsible for sales force support, incentive compensation and alliance management. Mr. Franklin received a BA from Gettysburg College in 1988.
Follow David Franklin:
About Intarcia Therapeutics: Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
Ved Srivastava
Vice President, Chemistry of Intarcia Therapeutics
Follow Ved Srivastava:
About Intarcia Therapeutics, U.S. Pharmacopeial Convention (The United States Pharmacopeial Convention): Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
Andrew Young
Vice President & Chief Scientific Officer of Intarcia Therapeutics
Dr. Young joined Intarcia in September 2015 as Vice President and Chief Scientific Officer. Dr. Young is most recognized for his role in the discovery and development of peptide therapeutics for metabolic diseases. Prior to its acquisition by Intarcia, he co-founded and was CSO of Phoundry Pharmaceuticals Inc., a company dedicated to rendering peptides sufficiently potent for incorporation into innovative delivery systems such as Intarcia’s proprietary mini-pump technology. Dr. Young entered industry from academia 26 years ago as the founding physiologist at Amylin Pharmaceuticals, Inc. There he pioneered work that illuminated the role of the gut in blood glucose control. He co-led different phases of the development of pramlintide and exenatide, first-in-class medicines for the treatment of diabetes. His roles at Amylin included VP of Research and Senior Research Fellow. In 2008 he co-founded Satiogen Inc., a San Diego startup related to bile salt stimulation of gut hormone secretion, before joining GlaxoSmithKline in RTP, NC, as Head of Enteroendocrine Biology. At GSK he fostered the development of peptide therapeutics as well as non-absorbed medicines acting at gut targets. In 2015 he co-founded Phoundry Pharmaceuticals with five former GSK colleagues. Dr. Young received his medical degree as well as graduate science degrees from the University of Auckland School of Medicine, New Zealand, where he also taught physiology. He worked as a Fogarty Fellow for the NIH in Phoenix AZ, studying diabetes in Pima Indians. He worked as a Von Humboldt Fellow at the Max Planck Institute in Bad Nauheim, FRG, studying sensory neurophysiology. He has participated in the development of five drugs that were commercialized, written over 100 original papers and 37 book chapters or books, and is an inventor on 56 issued US patents.
Follow Andrew Young:
About Intarcia Therapeutics, Satiogen Pharmaceuticals: Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
Thomas Alessi
Vice President, Development and Manufacturing of Intarcia Therapeutics
Dr. Alessi joined Intarcia in December 1997 as Executive Director, Regulatory Affairs and Drug Development and was promoted to Vice President, Development in February 2002 with responsibility for the areas of product development, project management, chemistry and manufacturing. Prior to joining Intarcia, Dr. Alessi served as the Senior Director, Regulatory Affairs, Quality Assurance and Project Management at Ansan Pharmaceuticals where he was responsible for successful IND filings and for managing five drug development programs with oversight of vendors for preclinical and clinical studies and manufacturing clinical supplies. Before joining Ansan, Dr. Alessi was Director of Regulatory Affairs and Quality Assurance at Glycomed, Inc. where his duties included oversight and compliance of clinical manufacturing. His previous experience includes regulatory affairs and drug discovery experience in large pharmaceutical companies. Dr. Alessi was Senior Manager of Regulatory Affairs for Schering-Plough working in the Anti-infectives, Allergy Products and Chemisty, Manufacturing, & Controls groups. While at Schering-Plough, Dr. Alessi had regulatory responsibilities for approval and launch of interferon alfa-2b for hepatitis C as well as for hepatitis B. In his CMC role, he served on separate committees for process development and production of solid oral dosage forms, inhaled products, creams and semisolid products and sterile dosage forms, in addition to regulatory review of the CMC sections of Schering-Plough INDs and NDAs. Prior to joining Schering-Plough, Dr. Alessi invented and patented several new families of antidiabetic drugs while working as a Senior Scientist in the drug discovery group at Wyeth-Ayerst. Dr. Alessi earned a B.S. degree at Allegheny College and an M.S. and a Ph.D. in organic synthetic chemistry from the University of Rochester.
Follow Thomas Alessi:
About Intarcia Therapeutics: Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
Neal Meropol
Vice President, Head of Medical and Scientific Affairs of Flatiron Health
Neal J. Meropol is a medical oncologist, clinical investigator and health outcomes researcher who serves as vice president of research oncology at Flatiron Health. In this role, he leads efforts to leverage Flatiron’s technology platforms and nationwide provider network to gain insights from real-world data that accelerate research and improve quality of care for cancer patients. Prior to joining Flatiron, Neal was professor and chief of the division of hematology and oncology at University Hospitals Cleveland Medical Center and Case Western Reserve University, and associate director for clinical research at the Case Comprehensive Cancer Center. Neal has a national reputation for his research contributions in gastrointestinal malignancies and health services research, including evaluation of new agents, predictors of response and outcome, development of tools to overcome barriers to clinical trial participation, and assessment of the economic impact of care. He currently serves as chair emeritus of the National Cancer Institute Gastrointestinal Cancer Steering Committee, which oversees the development of clinical trials in the publicly-funded clinical trials system. Neal recently completed a four-year term as an elected member of the American Society of Clinical Oncology Board of Directors. He has authored more than 250 manuscripts, book chapters, and editorials related to cancer prevention, treatment, decision making, and health economics. Neal received his undergraduate degree in philosophy from Princeton University and MD from Vanderbilt University. He was a resident in internal medicine at Case Western Reserve University, and completed hematology and medical oncology fellowships at the University of Pennsylvania. He spent a sabbatical at the Leonard Davis Institute of Health Economics at the Wharton School of the University of Pennsylvania.
Follow Neal Meropol:
About Flatiron Health: Flatiron Health is a healthcare technology company that aims to improve lives by learning from the experience of every cancer patient.
Marta Bralic
Senior Vice President of Business Development of Flatiron Health
Marta Bralic Kerns is the Founder & CEO at Pomelo Care. She attended Harvard University.
Follow Marta Bralic:
About Flatiron Health, Pomelo Care: Flatiron Health is a healthcare technology company that aims to improve lives by learning from the experience of every cancer patient.
Heather A. Brown
Senior Vice President, Market Access & Reimbursement of HeartFlow
Dr. Brown brings 10 years of experience in advanced medical imaging product development and service. She has held leadership roles in multiple startups and drove the development of AAA stent graft and TAVR planning applications as well as novel methods of assessing cardiac wall mechanics. Dr. Brown developed the first Volumetric Medical Imaging college accredited program at Jefferson Community and Technical College in 2005. She holds six patents. She received her B.S. degree in Mechanical Engineering from Michigan Technological University, and M.S. and Ph.D. degrees in Biomedical Engineering from Vanderbilt University.
Follow Heather A. Brown:
About HeartFlow: HeartFlow is a medical technology company that provides new methods of diagnosis and treatment of cardiovascular disease.
Tim Fonte
VP Customer Success of HeartFlow
Tim is start-up executive and engineer with experience from early-stage R&D through commercial operations. He has worked in the fields of healthcare, software, hardware, product design, and manufacturing. Tim is currently VP Customer Success at HeartFlow. He has co-founded a custom products company. He was a key individual in bringing two high-impact, award-winning, FDA-approved healthcare technologies from R&D to production and initial commercial use: first at Cameron Health and most recently as an early employee and leader at HeartFlow.
Follow Tim Fonte:
About HeartFlow: HeartFlow is a medical technology company that provides new methods of diagnosis and treatment of cardiovascular disease.
Blanca Baez
SVP, Global Head Pharma & Biotech of Molecular Health
Blanca Baez joined Molecular Health GmbH as SVP, Global Head Pharma & Biotech in 2016.
Follow Blanca Baez:
About Molecular Health: Molecular Health offers software solutions for evidence-based healthcare decision support and smarter drug development.
Jay Wohlgemuth
Chief Medical Officer, SVP R&D, Medical, Population Health of Quest Diagnostics
Jay Wohlgemuth, HealthTap’s Chief HealthCare Officer, has devoted his career to giving patients and doctors access to relevant information that can help them live longer, healthier, and happier lives. Prior to joining HealthTap, Jay Wohlgemuth served as the Chief Scientific Officer and SVP of R&D and Medical at Quest Diagnostics. Jay Wohlgemuth—who was named a Technology Pioneer by the World Economic Forum in Davos—earned his bachelor’s degree at Harvard and his M.D. and Cardiovascular Medicine specialty training at Stanford. Jay Wohlgemuth has deep experience in healthcare research and new product development. Among other accomplishments, Jay Wohlgemuth led all test development efforts and overseen major partnerships in healthcare at Quest Diagnostics, ran companion diagnostics and drug development programs at Genentech, and was a co-founder and head of R&D and medical for CareDx, which developed and commercialized first-of-its-kind molecular testing for transplant recipients that reduces the need for invasive biopsies and is now a standard of care around the world. Jay is a trustee of the Anne and Henry Zarrow Foundation and a board member for the Personalized Medicine Coalition.
Follow Jay Wohlgemuth:
About Quest Diagnostics: Quest Diagnostics is a clinical laboratory that offers diagnostic testing, services, and information.
Nigel Clarke
VP, R&D and Advanced Technology of Quest Diagnostics
Clarke received his Ph.D. in Mass Spectrometry and Analytical Chemistry from the University of Kent, United Kingdom and completed his postdoctoral fellowship training in Biomedical Mass Spectrometry at the Mayo Clinic. He was Principle Investigator at the Schering-Plough Research Institute in Kenilworth NJ, running the drug discovery metabolite identification group and worked at ActivX Biosciences as Director of Mass Spectrometry before joining Quest Diagnostics. Dr. Clarke is Vice President for Advanced Technology and Solution Development overseeing R&D groups developing LC-MS/MS, Microsampling, Infectious Disease and Immunology assays utilized across Quest Diagnostics. His staff trains visiting scientists from other Quest Diagnostics labs in adopting new technology and assays from his R&D groups. He also oversees the running of LCMS/MS assays across multiple operations laboratories within the Quest network as well as the Technology Transfer portion of the Global Diagnostic Network. He has published extensively in top tier journals and textbooks and is an internationally recognized speaker and award winner. He holds over 50 patents.
Follow Nigel Clarke:
About Quest Diagnostics, Quest Diagnostics: Quest Diagnostics is a clinical laboratory that offers diagnostic testing, services, and information.
Adam Bayaa
Vice President of IT & Security of Heal
Adam is Vice President of IT & Security at Heal, and has over 15 years’ experience in the retail, hospitality and healthcare industries.
Follow Adam Bayaa:
About Heal: Heal is an in-home primary care practice that offers modern doctor house calls, one-touch telemedicine and remote monitoring for seniors.
Mike Jensen
Senior Vice President of Operations of Heal
Follow Mike Jensen:
About Heal: Heal is an in-home primary care practice that offers modern doctor house calls, one-touch telemedicine and remote monitoring for seniors.
Charles Roberts
Co-Founder , Vice President and Chief Science Officer of DiabetOmics
Dr. Roberts is co-founder and chief science officer since 2008. Dr. Roberts is a molecular endocrinologist with over 25 years of experience in diabetes research, is an internationally recognized expert on insulin action, and has authored over 250 scientific papers and review articles. Dr. Roberts is also a co-inventor on various patents on therapeutics and biomarkers for clinical diagnostics, and serves on numerous review panels for the National Institutes of Health and the editorial boards of several major biomedical research journals. From 1984-1994, he was a Senior Investigator in the Diabetes Branch of the National Institutes of Health in Bethesda, MD, and subsequently Professor and Associate Chair for Research in the Department of Pediatrics and Professor of Medicine at Oregon Health & Science University.
Follow Charles Roberts:
About DiabetOmics: DiabetOmics is a medical diagnostics company that provides non-invasive assessment and management of personalized health and diabetes risk.
George Winston
Senior Vice President / General Manager Acute Care Division of Sommetrics
33 years in healthcare commerce, including sales, sales management, marketing, marketing management, with Sorenson Research, Abbott Laboratories and Hospira Worldwide and 5i Sciences. This experience spans across several medical device product lines for the hospital critical care, CV surgery, and CV anesthesia markets. The product lines include physiological pressure measurement, continuous mixed venous oxygen saturation monitoring, electronic infusion devices, airway management, sleep apnea and CV Surgery devices. Net result of the assignments is a thorough understanding of the acute care hospital market, with special knowledge of physician and nursing technology needs along with designing and selling products into the anesthesia, critical care and CV surgery areas. Currently V.P. Marketing, 5i Sciences, a medical device start-up with a focus on OSA and airway management in sedated patients, undergoing medical procedures. Experienced in partnership and financial discussions with major potential corporate partners and investors. Areas of experience include: Establishment of a regional critical care sales force with top and bottom line sales accountability, establishment of a KOL referral program, development of sales and product training materials and participation in the product design process, with focus on product usability to enhance clinician acceptability. Education: 1972 – 1975 Florida Atlantic University, Boca Raton, Florida Marketing and business, 1969 – 1971 Miami – Dade College, Miami, Florida A.A.S., Aeronautical Technology. FAA flight certifications include Commercial license, Flight instructor, Instrument flight instructor.
Follow George Winston:
About Adela Health Inc., Keiretsu Forum, Sommetrics, TruPosture: Sommetrics is focused on improving health and well-being by optimizing sleep quality.
Frédéric Sweeney
Vice President, Corporate Development & Strategic Financing Lead of bioMerieux
Dr. Frédéric Sweeney is the vice president, corporate development and strategic financing lead of bioMerieux. Prior to joining bioMerieux, Fred was Vice-President of Business Development & Strategic Alliances for Tornado Spectral Systems (TSS), a commercial stage nanophotonics and spectroscopy technology company strongly driven by an OEM partnership business model. Having joined as an original founding member of the company, Fred managed all aspects of commercialization and go-to-market strategy for TSS’ product portfolio. He led a number of large partnership agreements with world-leading spectroscopy companies and several in/out-licensing deals. Fred also worked as part of the life sciences investment team at VenGrowth Private Equity Partners, one of Canada’s premier private equity and venture capital firms. His main responsibilities at VenGrowth were to provide operational support and coordinate follow-on investments for portfolio companies, as well as sourcing and performing due diligence on new investment opportunities for the firm. Fred also acted as an observer on the Board of numerous companies in the medical device, therapeutic, diagnostic and biomaterials space. Fred holds a Ph.D. in molecular and medical genetics from the University of Toronto as a Terry Fox Scholar of the National Cancer Institute of Canada. During his scientific training, he acquired a deep expertise in clinical diagnostics and cancer biology by using structural and molecular biology as well as small molecule biochemistry.
Follow Frédéric Sweeney:
About bioMerieux: bioMérieux develops and produces in vitro diagnostic solutions for private and hospital laboratories, mainly for the diagnosis.
Jeffrey Nathanson
Vice President, Business Development of 10.10.10
Follow Jeffrey Nathanson:
About 10.10.10: 10.10.10 gives impact entrepreneurs the context and tools to develop market-based solutions.
Joseph Talamo
Senior Vice President and Chief Financial Officer of HiberCell
Joseph Talamo is the Senior Vice President and Chief Financial Officer at HiberCell.
Follow Joseph Talamo:
About HiberCell: HiberCell is a biotechnology company developing treatments to prevent cancer relapse and metastasis.
Satnam Alag
Senior Vice President Software Engineering and Chief Security Officer of Grail
Dr. Alag is a software professional with over fifteen years of commercial software development and management experience, with over twenty years of experience in machine learning and search areas. His expertise is in Big Data technologies, building large-scale multi-tenant SaaS applications, applying intelligence and personalization to Web 2.0 applications, SOA and J2EE architectures, delivering high-quality software, and building high performing engineering teams. He is currently the CTO and VP of Engineering at NextBio. NextBio is a data-driven engine, which is at the intersection of Big Data and genomics. At NextBio, he leads a team that mines billions and billions of data points using the Hadoop stack and commodity hardware. Prior to joining NextBio, he worked as a consultant with Johnson and Johnson’s BabyCenter where he helped develop their personalization engine. Prior to that, he was the Chief Software Architect and Dir. of Application Engineering at Rearden Commerce. He began his career at GE R&D and has held senior technical and management positions at Computing Technologies International and Black Pearl. Satnam is a Sun Certified Enterprise Architect (SCEA) for the Java platform. His doctoral dissertation from the University of California, Berkeley was in the area of probabilistic reasoning and machine learning. He has a number of peer-reviewed publications, holds five patents. He is the author of the book “Collective Intelligence in Action”.
Follow Satnam Alag:
About Grail, Zenufa Laboratories: Grail develops a pan-cancer screening test designed to detect cancers at an early stage.
Dave Anderson
Senior VP of Engineering & Chief Operating Officer of Atonarp
Follow Dave Anderson:
About Atonarp: Atonarp combines electronics and data processing algorithms for chemical composition analysis.
Lynn Crowe
Senior Vice President, Member Advocacy of Livongo
With over 20 years as a healthcare professional focused in diabetes, Lynn has successfully led programs to reduce barriers to proper care for people with diabetes. Starting her career with the American Diabetes Association, Lynn developed programs that were adopted as national prototypes, some of which are still in place today. Upon obtaining her Masters degree in counseling, Lynn joined Sanofi’s diabetes division where she honed her insights into the person with diabetes. She led programs with proven success addressing the psychological challenges of the diseases. Lynn has been recognized as an innovator in the diabetes space receiving numerous awards. In 2011, she co-authored and published “The Diabetes Manifesto: Take Control of Your Life”, a book that has been well received by the community. Upon joining Livongo in 2013, she has helped build Livongo’s client experience and now primarily focuses on member advocacy, ensuring the “Member First” philosophy is incorporated in all we do. Lynn holds a Bachelor of Science in Business and Master of Science in Counseling from the University of Scranton.
Follow Lynn Crowe:
About Livongo: Livongo provides a data science and technology enabled platform for detection of diabetes.
Frank Shields
Vice President of US Sales of Ivantis
Frank Shields currently works as Vice President of US Sales at Ivantis.
Follow Frank Shields:
About Ivantis: Ivantis is focused on developing an innovative treatment for glaucoma which includes eye drops, laser therapy, and surgery.
Richard Hope
Vice President of Clinical and Medical Affairs of Ivantis
Richard Hope currently works as Vice President of Clinical & Medical Affairs at Ivantis.
Follow Richard Hope:
About Ivantis: Ivantis is focused on developing an innovative treatment for glaucoma which includes eye drops, laser therapy, and surgery.
Ken Galt
Vice President of Research and Development of Ivantis
Ken Galt currently works as Vice President of Research and Development at Ivantis.
Follow Ken Galt:
About Ivantis: Ivantis is focused on developing an innovative treatment for glaucoma which includes eye drops, laser therapy, and surgery.
Paul Epner
Executive Vice President of Xip
Follow Paul Epner:
About Society to Improve Diagnosis in Medicine, Xip: Xip produces disposable blood analyzers that wirelessly upload lab-quality clinical measurements in minutes.
John Cerio
Senior Vice President and Global Head of Human Resources of Orchard Therapeutics
John brings over 25 years of HR leadership experience in the pharmaceutical and biotech industry building high growth, high performance, mission driven and entrepreneurial companies. Until recently John served as Vice President of Human Resources and Administration for Agenus where he led the HR function through periods of rapid growth, transformation and global expansion including the acquisition and integration of 4-antibody AG and the recruiting and on-boarding of over 150 R&D staff, responsible for creating and advancing an Immuno-oncology portfolio of over a dozen clinical candidates including 4 that are currently in phase 2. Prior to Agenus, he was Vice President of Global HR for PerkinElmer Life Sciences during which time the company more than doubled in size and annual sales. Earlier in his career, John spent nearly 10 years with Bristol-Myers Squibb company in a series of HR leadership roles with increasing responsibilities ranging from Director of HR for Corporate Staff to Head of HR for their Oncology and Immunology division. John earned his B.S. in Industrial and Labor Relations from Cornell and his M.A. in Organizational Psychology from Columbia. He also completed the Global Leadership Development Programme at the London Business School.
Follow John Cerio:
About Orchard Therapeutics: Orchard Therapeutics is a biotechnology company dedicated to transforming the lives of patients through innovative gene therapies.
Daniel Simon
Senior Vice President, BioPharma Business Development of Guardant Health
Follow Daniel Simon:
About Guardant Health: Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs in oncology.
Marcelo Trevino
Global VP, Regulatory Affairs & Quality Assurance of Agendia
Marcelo Trevino serves as the Global Vice President of Regulatory Affairs and Quality Assurance at Agendia.
Follow Marcelo Trevino:
About Agendia: Agendia provides molecular diagnostics and personalized treatment plans for cancer patients.
Raul Krauss
Co-Founder & Vice President of Disarm Therapeutics
Follow Raul Krauss:
About Disarm Therapeutics: Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Raul Krauss
Co-Founder & Vice President of Disarm Therapeutics
Follow Raul Krauss:
About Disarm Therapeutics: Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Carol Penfold-Patterson
Founder and VP of Marketing of IncellDx
Follow Carol Penfold-Patterson:
About IncellDx: IncellDx is a molecular diagnostics company focused on the detection and monitoring of life threatening viral diseases.
Graham Lidgard
Senior Vice President R&D and Chief Science Officer of Exact Sciences
Follow Graham Lidgard:
About Exact Sciences: Exact Sciences is the developer and manufacturer of Cologuard, a non-invasive screening test for the early detection of colorectal cancer.
Adam Logal
Sr. Vice President & Chief Financial Officer of OPKO Health
Mr. Logal has served as OPKO’s Sr. Vice President and Chief Financial Officer since April 2014 and as OPKO’s Vice President of Finance, Chief Accounting Officer and Treasurer since March 2007. From 2002 to 2007, Mr. Logal served in senior management of Nabi Biopharmaceuticals, a publicly traded, biopharmaceutical company engaged in the development and commercialization of proprietary products. Mr. Logal held various positions of increasing responsibility at Nabi Biopharmaceuticals, last serving as Senior Director of Accounting and Reporting. Mr. Logal currently serves on the board of directors of SciVac Therapeutics, Inc. (TSX: VAC), a commercial-stage biopharmaceutical company.
Follow Adam Logal:
About OPKO Health: Opko Health engages in the discovery and development of novel and proprietary technologies for pharmaceuticals and diagnostics.
Steven Rubin
Executive Vice President of OPKO Health
Mr. Rubin has served as Executive Vice President – Administration since May 2007 and as a director of the Company since February 2007. Mr. Rubin served as the Senior Vice President, General Counsel and Secretary of IVAX from August 2001 until September 2006. Mr. Rubin currently serves on the board of directors of SciVac Therapeutics, Inc. (TSX: VAC), a commercial-stage biopharmaceutical company, Tiger Media, Inc. (NYSE MKT:IDI), a multi-platform media company, Kidville, Inc. (OTCBB:KVIL), which operates large, upscale facilities, catering to newborns through five-year-old children and their families and offers a wide range of developmental classes for newborns to five-year-olds, Non-Invasive Monitoring Systems, Inc. (OTCBB:NIMU), a medical device company, Tiger X Medical, Inc. (OTCBB:CDOM), previously an early-stage orthopedic medical device company specializing in designing, developing and marketing reconstructive joint devices and spinal surgical devices, Cocrystal Pharma, Inc. (OTCBB: COCP), formerly Biozone Pharmaceuticals, Inc., a publicly traded biotechnology company developing new treatments for viral diseases, Sevion Therapeutics, Inc. (OTCBB:SVON), a clinical stage company which discovers and develops next-generation biologics for the treatment of cancer and immunological diseases, Castle Brands, Inc. (NYSE MKT:ROX), a developer and marketer of premium brand spirits, and Neovasc, Inc. (TSXV:NVC), a company developing and marketing medical specialty vascular devices. Mr. Rubin previously served as a director of Dreams, Inc. (NYSE MKT: DRJ), a vertically integrated sports licensing and products company, Safestitch Medical, Inc. prior to its merger with TransEnterix, Inc., and PROLOR Biotech, Inc., prior to its acquisition by the Company in August 2013.
Follow Steven Rubin:
About OPKO Health: Opko Health engages in the discovery and development of novel and proprietary technologies for pharmaceuticals and diagnostics.
Bhavesh Patel
VP, Digital Health of Outset Medical
Bhavesh Patel is the VP, Software, Analytics, Mobile at Outset Medical, Inc. Bhavesh’s career spans executive leadership roles from Fortune 100 company (Walmart) to startup company (Ventro). He achieved high-business growth through state-of-the-art technology solutions, keen people leadership and strong business acumen. He drove successful executions, solving complex challenges and creating a competitive advantage – delivering multibillion-dollar growth. His diverse industry experience enables a consumer-minded approach to design Tablo’s highly fault-tolerant system and cloud-based ecosystem products.
Follow Bhavesh Patel:
About Outset Medical: Outset Medical is a pioneering medical technology company that manufactures medical equipment.
Kulwant Sandhu
VP, Integrated Supply Chain of Outset Medical
Follow Kulwant Sandhu:
About Outset Medical: Outset Medical is a pioneering medical technology company that manufactures medical equipment.
Tim Kanter
Vice President Market Access, Trade and Pricing of Orphazyme
Tim Kanter is the CCO of Prescient Medicine, a company focused on producing tools that target patient outcomes and management in two key areas – medication interaction and medication efficacy –including the validated genetic test designed to predict individual risk of opioid addiction, LifeKit® Predict. Tim has worked for major pharmaceutical and biopharmaceutical companies including Baxalta/Baxter, Novo Nordisk, and ALTANA Pharma in both US and global roles. Most recently, he consulted with a variety of companies in the preparation and launch of new products and initiatives within multiple therapeutic areas. Tim holds a BS from the University of Florida and an MBA from the University of South Florida.
Follow Tim Kanter:
About Orphazyme: Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disorders called lysosomal storage diseases.
Anjen Chenn
Senior Vice President of Metamark Genetics
Follow Anjen Chenn:
About Metamark Genetics, University of Illinois at Chicago: Metamark Genetics develops prognostic and predictive diagnostic tests that enable personalized treatment planning for cancer patients.
John Mcmannis
Executive Vice President, Manufacturing of Mesoblast
Follow John Mcmannis:
About Mesoblast: Mesoblast is a medicine company that develops biologic products for the broad field of regenerative medicine.
Daniel Cher
Vice President, Clinical Affairs of SI-BONE
Daniel Cher is a board-certified internist with over 15 years of clinical affairs and research experience in a variety of medical device technology companies. His experience includes developing clinical and regulatory strategy, designing and leading clinical trials, directing clinical research, and consulting with a variety of medical device technology companies. Most recently, he served as VP of Clinical and Regulatory Affairs at Chestnut Medical, an early-stage company developing new minimally invasive therapies for Interventional Neuroradiology. At Chestnut, he lead clinical trials and regulatory affairs for the Pipeline Embolization Device, a novel device for the treatment of large and giant intracranial aneurysms, which received FDA approval in April 2011. Prior to this, Dr. Cher served as VP of Clinical and Regulatory Affairs at Pulmonx, Inc., and was Medical Director and VP of Clinical Research at Kyphon, Inc., where he directed clinical research. Educated at Stanford and Yale Universities, Daniel pursued his residency in internal medicine at University of Wisconsin, Madison, and California Pacific Medical Center, in San Francisco. Daniel underwent additional training in general internal medicine and research methods at Stanford University and the Palo Alto VA Hospital. Daniel left clinical practice in 1999 to lead clinical trials at several San Francisco Bay Area medical device technology companies, including Kyphon. Daniel’s focus is on clinical trial design and statistical analysis.
Follow Daniel Cher:
About PROCEPT BioRobotics, SI-BONE, Wild Iris Consulting: SI-BONE advances the diagnostic understanding of lower back pain and minimally invasive surgery for the sacroiliac joint.
Scott Yerby
Vice President, Chief Technology Officer of SI-BONE
Scott Yerby has served in an R&D position for several start-up medical device companies for the past 10 years. Most notably, he served as the VP of R&D for St. Francis Medical Technologies, until its acquisition by Kyphon in 2007. Scott has co-authored over 40 peer reviewed publications, 70 abstracts, and 60 patent applications, and been issued 17 patents for a variety of medical technology companies. Prior to entering the medical device technology industry, Dr. Yerby served as the Director of Experimental Biomechanics at the Palo Alto VA Hospital for three years. He has also held appointments as Consulting Assistant Professor at Stanford University in the Department of Mechanical Engineering, Division of Biomechanical Engineering, as well the Department of Functional Restoration, Division of Orthopedic Surgery. Dr. Yerby holds B.S. and M.S. degrees in Mechanical Engineering, and a Ph.D. in Biomedical Engineering, all from University of California, Davis.
Follow Scott Yerby:
About SI-BONE: SI-BONE advances the diagnostic understanding of lower back pain and minimally invasive surgery for the sacroiliac joint.
John Mulcahy
Vice President, Research of SiteOne Therapeutics
John Mulcahy PhD, is a Co-Founder and Vice President of Research at SiteOne. As a postdoctoral fellow and graduate student at Stanford, he developed methods for preparing a family of rare, naturally occurring sodium ion channel pore blockers from simple starting materials. He received his A.B. degree from Harvard University, with concentrations in Chemistry, Physics, and the Classics. Honors include a Stanford Dean’s Postdoctoral Fellowship, a National Science Foundation Predoctoral Fellowship, a Pfizer Summer Research Fellowship and a National Merit Scholarship. Dr. Mulcahy is also a Principal Investigator on multiple small business grants awarded to SiteOne by The National Institutes of Health.
Follow John Mulcahy:
About SiteOne Therapeutics, StartX (Stanford-StartX Fund): SiteOne Therapeutics is a San Francisco-based company that develops novel therapeutics and diagnostics.
Martin C. Peters
VP, US Neuroscience Strategy & New Product Launches of Takeda
Martin C. Peters has over 12 years of professional experience developing and commercializing healthcare products from first-in-man through launch and life-cycle management. Martin is currently the Sr. Director of Program Leadership & Management at Biogen Idec and prior to this has served as Vice President of US Marketing for Novartis Vaccines, Sr. Director of Strategic Marketing for Aastrom Biosciences and as a Project Leader with the Boston Consulting Group. He holds a PhD from the University of Michigan where he was a Whitaker Foundation Fellow working on cell therapy for tissue engineering applications. He currently has six patents and over a dozen peer-reviewed articles covering cell therapy-related topics.
Follow Martin C. Peters:
About Takeda: Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company in Japan.
